Community-acquired pneumonia in children


DOI: https://dx.doi.org/10.18565/pharmateca.2021.1.68-74

A.A. Tkacheva, A.S. Polyakova, M.D. Bakradze, V.K. Tatochenko, D.S. Yasakov

National Medical Research Center for Children’s Health, Moscow, Russia
Background. Community-acquired pneumonia (CAP) is still one of the most common acute infectious diseases of childhood in the world. Despite the vaccination, infant mortality from pneumonia still remains at a significant level. Timely diagnosis and the appointment of adequate antibiotic therapy are the key factors for the success of treatment and the prognosis of the disease. Despite progress in the field of laboratory and instrumental diagnosis of pneumonia, etiological diagnosis often depends on the clinical picture of the disease, and the selection of the antibiotic is carried out empirically.
Objective: improve the efficiency of differential diagnosis of acute pneumonia in pediatric practice.
Methods. This article presents the results of a retrospective analysis of the case histories of 140 children aged 9 months to 17 years with a diagnosis of CAP, hospitalized in the Department of Diagnostics and Rehabilitation Treatment, National Medical Research Center for Children’s Health, from January 2016 to January 2020.
Results. The etiological structure was assessed, the age-related characteristics of CAP were shown, the spectrum of antibacterial drugs prescribed at the prehospital stage, their dosage and effectiveness were studied.
Conclusion. According to the clinical European and American guidelines, aminopenicillins are the drug of choice for the treatment of typical CAP of both pneumococcal and hemophilic etiology due to the highest activity against these pathogens and the safety of use.
Keywords: pneumonia in children, antibiotic therapy, amoxicillin, amoxicillin/clavulanate, antibiotic resistance

About the Autors


Corresponding author: Anna A. Tkacheva, Pediatrician, Department of Diagnostics and Rehabilitation Treatment, National Medical Research Center for Children’s Health, Moscow, Russia; antkacheva.med@gmail.com
Address: build. 1, 2 Lomonosovsky Prospect, Moscow 119991, Russian Federation


Бионика Медиа